GYRE THERAPEUTICS, INC. (GYRE): Submission of Matters to a Vote of Security Holders
GYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001124105 NASDAQ 0001124105 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1
How this was made
The 30-second read
Why it matters
The key incremental governance/corporate action is approval of the conversion of Series B convertible preferred stock into common stock under Nasdaq Listing Rule 5635(a).
Market read
Routine annual meeting outcomes with a capital-structure-related approval (Series B conversion), but no conversion terms are disclosed in the excerpt.
What to watch
Traders may want to cross-check the April 27, 2026 definitive proxy for the Series B conversion mechanics (conversion ratio, number of shares, and expected issuance timing), which are not included in this 8-K voting-results excerpt.
Background
This SEC 8-K reports the final voting results from Gyre Therapeutics’ 2026 Annual Meeting of Stockholders held June 10, 2026.
Ticker impact
Gyre Therapeutics filed an 8-K confirming its 2026 annual meeting results, including director elections and approval of Series B conversion.
Likely limited near-term impact; Series B conversion approval could modestly affect capital structure/dilution expectations, but no conversion terms or timing are provided here.
The filing is a primary SEC disclosure of voting outcomes, but it lacks incremental deal terms (e.g., conversion ratio, issuance size, or effective date) that would typically drive a larger repricing.
Market effects
Minimal; governance and preferred conversion approval is company-specific and not a sector-wide regulatory/clinical catalyst.
Minimal; no broader regional macro or peer read-across is provided.
Minimal; no international transaction or cross-border regulatory action is described.
Counterpoint
The Series B conversion approval may be more meaningful than it appears, potentially signaling imminent common issuance and dilution risk even though the filing omits conversion size/timing details.
Key entities
- issuerGyre Therapeutics, Inc.
Company filing the 8-K; held its 2026 annual meeting and reported final voting results.
- securitySeries B Convertible Preferred Stock
Preferred class whose conversion into common stock was approved by shareholders.
- auditorGrant Thornton Zhitong Certified Public Accountants LLP
Independent registered public accounting firm ratified for the year ending December 31, 2026.
